Range verification for eye proton therapy based on proton-induced x-ray emissions from implanted metal markers.
Metal fiducial markers are often implanted on the back of the eye before proton therapy to improve target localization and reduce patient setup errors. We aim to detect characteristic x-ray emissions from metal targets during proton therapy to verify the treatment range accuracy. Initially gold was chosen for its biocompatibility properties. Proton-induced x-ray emissions (PIXE) from a 15 mm diameter gold marker were detected at different penetration depths of a 59 MeV proton beam at the CATANA proton facility at INFN-LNS (Italy). The Monte Carlo code Geant4 was used to reproduce the experiment and to investigate the effect of different size markers, materials, and the response to both mono-energetic and fully modulated beams. The intensity of the emitted x-rays decreases with decreasing proton energy and thus decreases with depth. If we assume the range to be the depth at which the dose is reduced to 10% of its maximum value and we define the residual range as the distance between the marker and the range of the beam, then the minimum residual range which can be detected with 95% confidence level is the depth at which the PIXE peak is equal to 1.96 σ(bkg), which is the standard variation of the background noise. With our system and experimental setup this value is 3 mm, when 20 GyE are delivered to a gold marker of 15 mm diameter. Results from silver are more promising. Even when a 5 mm diameter silver marker is placed at a depth equal to the range, the PIXE peak is 2.1 σ(bkg). Although these quantitative results are dependent on the experimental setup used in this research study, they demonstrate that the real-time analysis of the PIXE emitted by fiducial metal markers can be used to derive beam range. Further analysis are needed to demonstrate the feasibility of the technique in a clinical setup.
Department of Medical Physics and Bioengineering, University College London, WC1E 6BT, UK.
Vanessa
V
La Rosa
Andrzej
A
Kacperek
Gary
G
Royle
Adam
A
Gibson
D005123:Eye / Q000528:radiation effects*; D005240:Feasibility Studies; D057918:Fiducial Markers; D006046:Gold; D008545:Melanoma / Q000532:radiotherapy; D009010:Monte Carlo Method; D061766:Proton Therapy / Q000592:standards*; D012834:Silver; D014604:Uveal Neoplasms / Q000532:radiotherapy; D014965:X-Rays; D000098943:Uveal Melanoma
D012834:Silver; D006046:Gold